414 related articles for article (PubMed ID: 33160859)
1. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
5. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
[TBL] [Abstract][Full Text] [Related]
6. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
[TBL] [Abstract][Full Text] [Related]
7. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
8. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
10. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
[TBL] [Abstract][Full Text] [Related]
11. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
13. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
14. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
15. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
[TBL] [Abstract][Full Text] [Related]
16. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of peritumoral vascular and intratumoral radiomics to predict pathologic complete responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Xie T; Gong J; Zhao Q; Wu C; Wu S; Peng W; Gu Y
BMC Med Imaging; 2024 Jun; 24(1):136. PubMed ID: 38844842
[TBL] [Abstract][Full Text] [Related]
20. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
